Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 11, 2015 10:02 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics' Lead Immunoconjugate Continues to Demonstrate Complete Tumor Regressions in Multiple HER2-Expressing Breast Cancer Tumor Models

Data validate the potential of XMT-1522 to expand number of patients who may benefit from HER2-targeted therapies IND anticipated mid-2016 CAMBRIDGE, Mass., Dec. 11, 2015 (GLOBE NEWSWIRE) --...
November 30, 2015 16:30 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present Poster at the 2015 San Antonio Breast Cancer Symposium

CAMBRIDGE, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that it will present a poster at the 2015 San Antonio Breast Cancer Symposium, taking place December...
October 15, 2015 16:30 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at World ADC San Diego

CAMBRIDGE, Mass., Oct. 15, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced its presentation at World ADC San Diego, taking place October 19-22, 2015, at the Sheraton San Diego...
April 17, 2015 16:21 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics' Lead Fleximer(R) Immunoconjugate Demonstrates Potent Activity in Low HER2-Expressing Tumor Models

– XMT-1522 Designed to Expand Patient Population Treated With HER2-Targeted Therapy – – Complete Tumor Regressions Observed in HER2 1+ and 2+ Cancer Models Refractory to Current...
April 15, 2015 09:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present Late-Breaking Poster at AACR Annual Meeting 2015

CAMBRIDGE, Mass., April 15, 2015 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. today announced that it will present two posters, including a late-breaker with data from its lead immunoconjugate...